Our findings indicate that direct activation of AMPK in the liver might provide an attractive therapeutic strategy for preventing progression of NAFLD and subsequent development of associated complications. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatotic liver disease.